With energy prices, inflation trends and central bank signals all pulling markets in different directions, many investors are looking for stocks where analysts still see solid earnings growth potential backed by reasonable balance sheets. That is exactly what the Healthy high growth potential screener focuses on, highlighting companies that meet analyst expectations for strong earnings growth over the next 3 years and that also sit in an acceptable financial position. In this article, you will see 3 of the stocks from this screener that aim to combine growth potential with financial resilience.

Kioxia Holdings (TSE:285A)

Overview: Kioxia Holdings is a Tokyo based memory manufacturer that produces flash memory chips and solid state drives used in consumer electronics, industrial systems, cars, and data centers worldwide, including its own BiCS FLASH technology and enterprise grade SSDs for cloud and AI workloads.

Operations: Kioxia generates all of its reported revenue of ¥2,337,628m from its Memory Business segment, which includes NAND flash and SSD products.

Market Cap: ¥49.6t

Kioxia Holdings appears in the Healthy high growth potential screener because its core memory business is closely tied to AI data storage. Recent headlines have noted that it briefly became Japan’s most valuable listed company as investors focused on AI linked semiconductors. Analysts currently expect earnings and revenue to grow at rates above the wider Japanese market, supported by a net profit margin of 23.7% and a forecast ROE in the mid 40% range. However, the stock trades on a high P/E and carries a heavy debt load that raises funding risk. Together with very sharp recent share price swings and limited board independence, this creates a powerful but complex growth story that may warrant closer inspection.

Kioxia’s AI linked momentum, high forecast ROE and rich P/E raise a clear question for growth focused investors, and the analyst forecasts for Kioxia Holdings may reveal whether those expectations are masking a critical twist.

Aris Mining (TSX:ARIS)

Overview: Aris Mining is a Vancouver based gold producer that acquires, explores, develops, and operates gold mines in Colombia, Guyana, and Canada, with additional exposure to silver and copper.

Operations: Aris Mining generates about $1.14b in revenue, primarily from its Segovia operations at $1,031.6m and Marmato at $111.0m in Colombia.

Market Cap: CA$4.6b

Aris Mining stands out in the Healthy high growth potential screener because it combines meaningful production growth projects at Segovia and Marmato with improving profitability, shown by a 15.2% net margin and a strong recent quarter where Q1 2026 revenue reached $372.5m with net income of $97.6m. Analysts currently model rapid earnings expansion, and the stock is still valued below some estimates of its future cash flows. At the same time, investors need to weigh clear risks such as reliance on Colombian assets, exposure to gold prices, funding needs, and recent shareholder dilution. For those willing to accept these trade offs, the ramp up toward Marmato’s first gold and the potential impact on Aris Mining’s long term earnings may be an important part of the story.

Aris Mining’s accelerating project pipeline and recent Q1 2026 results suggest that the real story may be how future production could reshape its earnings profile, and the analyst forecasts for Aris Mining could reveal the crucial twist investors are missing

Insulet (PODD)

Overview: Insulet is a medical device company that makes the Omnipod family of tubeless insulin pumps, using automated insulin delivery technology that links to continuous glucose monitors to help people with insulin dependent diabetes manage their blood sugar. It also supplies disposable drug delivery pods to partners such as Amgen and sells primarily through pharmacies and distributors in the US and overseas.

Operations: Insulet generates about US$2.9b in revenue from Drug Delivery Systems, with roughly US$2.1b from the United States and US$844.9m from international markets.

Market Cap: US$10.4b

Insulet stock earns a place in the Healthy high growth potential screener because Omnipod 5 is helping it tap a large and underpenetrated type 2 diabetes market. In addition, new data on Omnipod 6 and fully closed loop systems points to more product depth ahead. Earnings and revenue are both forecast to grow faster than the wider US market, ROE is projected around 22.1%, and Simply Wall St’s model suggests the shares trade well below an estimate of fair value. At the same time, recent margin pressure, a voluntary device correction affecting millions of pods, and heavy reliance on a single platform show that execution and product safety are important considerations. The key question for investors is how those growth drivers and risks balance out over the next few years.

Insulet’s accelerating push into type 2 diabetes with Omnipod 5 and 6 could be masking a bigger story about growth, margin pressure and product risk, and the analyst forecasts for Insulet hints at the twist investors keep overlooking

The three stocks covered here are just a starting point. The full Healthy high growth potential screener surfaces 1,519 more companies where analysts see strong earnings growth potential backed by acceptable financial positions, and you can review that wider list through the Healthy high growth potential screener. Identify and analyze the specific catalysts, balance sheet traits, and earnings narratives that matter most to you so you can focus on the highest conviction ideas rather than a noisy watchlist.

Take Control of Your Investment Journey

If Aris Mining or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh stock ideas can move from quiet to flying once momentum builds, and late entries often get caught chasing. Scan these under the radar picks while it matters, act now.

• Spot sturdy compounders early by scanning a curated list of solid balance sheet and fundamentals (40 results) that keeps financial strength at the center of every potential pick.
• Ride income trends by targeting a hand picked 49 dividend fortresses built to highlight consistency, coverage, and resilience.
• Position beside long term builders by reviewing a focused 11 top founder-led companies where founder commitment and aligned incentives guide every short list candidate.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.